Technicals look fairly good, but perhaps slightly over-brought in the near term.
GILD's monster quarter helped the shares jolt upward and break through the medium-term downtrend that hit the stock after fears over margins for Harvoni & Sovaldi. - Q1 Earnings: Decimated Revs & EPS -Q1 Earnings:Margins not hit as badly as expected -HIV & Nash mitigate one trick pony risk -Shrewd management that has avoided expensive M&A, and has historically made excellent acquisition decisions (e.g. Pharmasset in 2011) If the recent moves into oncology by acquiring EpiTherapeutics prove to be anywhere near as -fruitful as Hep-C, shareholders will profit handsomely. -Although the recent foray into Hep-B was unsuccessful, this is an area to look out for (huge growth opportunity)